Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 6Tumor-Agnostic 3Other solid neoplasm 3CNS 3Thoracic 2Gynecologic 2Classical hematology 1

Conditions

Squamous Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × iniparib × Thoracic × Clear all
NCT01082549 2016-03-17

ECLIPSE

Sanofi

Phase 3 Completed
780 enrolled
Thoracic

Squamous Cell Lung Cancer

NCT01086254 2013-09-24

SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer

Sanofi

Phase 2 Completed
119 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡